Rheumatology in Perspective · by Olga Goodman, MD · A RheumaView publication
What Can Blood Tests and HLA-B27 Tell Us?
A blood result can support a clinical picture, raise a new question or help make treatment safer. It cannot replace the story and examination of a growing child.
Start with the question, not the red flag on the screen
A parent opens a laboratory report and sees a result marked “positive”. A teenager hears that their inflammation tests are normal and wonders whether anyone will still believe the pain. Both situations deserve an explanation. The useful starting question is: what was this particular test meant to tell us?
Tests in juvenile spondyloarthritis (JSpA) have different jobs. Some help investigate the diagnosis. Others follow inflammation or check whether treatment is affecting blood cells, the liver or kidneys. A result may be important for one job without answering the others. Keep the test’s purpose beside the number when discussing it.
ESR and CRP are clues about inflammation
ESR, sometimes called the sedimentation rate, and CRP are blood markers that can rise with inflammation. They do not tell the clinician exactly where the inflammation is or what caused it. An infection may raise them too. The team interprets them alongside current symptoms, examination findings, recent illness and previous results.
Normal ESR or CRP does not rule out JSpA or prove that every inflamed joint or attachment has settled. A swollen knee or a persistent change in walking still needs attention. Equally, an unexpectedly raised result is a reason to understand the whole situation, rather than automatically label it an arthritis flare.
HLA-B27 is an inherited marker
HLA proteins help the immune system distinguish the body’s own cells from other material. HLA-B27 is one version of these proteins, determined by inherited genes. It is associated with several conditions in the spondyloarthritis family, but it is also present in healthy people.
A positive test means the marker was found. It does not mean that an infection has been found, that a child definitely has arthritis, or that the family caused the illness. The marker’s meaning depends on why testing was considered in the first place. Persistent joint swelling and a characteristic clinical history make a different setting from an isolated ache after sport.
Neither result provides the whole answer
A positive HLA-B27 result may add support to a diagnosis when the child’s symptoms and examination fit. It cannot establish JSpA on its own, predict the child’s individual future or show how severe today’s inflammation is. A negative result also does not exclude JSpA. The clinician may still have good reasons to investigate the joints, entheses or sacroiliac joints.
HLA-B27 is not a treatment-response marker to watch rising and falling. Keep the original result with its date so that it is available at future appointments. If repeat testing is proposed, ask which uncertainty the repeat would resolve. This is different from repeating inflammatory markers or medicine-safety tests.
Other blood tests answer different questions
A full blood count looks at blood cells. Other tests may assess liver or kidney function. They can contribute to the initial assessment or become part of monitoring a particular medicine. The choice and timing depend on the clinical question and treatment; every child does not need every available test.
Families also hear about ANA, rheumatoid factor or anti-CCP. These are not interchangeable “arthritis tests”. Their usefulness depends on the suspected condition. For example, ANA can help inform uveitis-screening decisions in some forms of juvenile idiopathic arthritis; it does not diagnose JSpA. Ask what an unexpected result changes in your child’s assessment or follow-up.
Bring a family history without turning it into a forecast
Tell the team about close relatives with diagnosed spondyloarthritis, psoriasis, inflammatory bowel disease or uveitis. If possible, use the diagnosis rather than “bad joints”, and say which relative was affected. An uncertain family memory can be recorded as uncertain; you do not need to reconstruct everyone’s medical records.
Family clustering is meaningful, but inheriting a marker is different from inheriting an inevitable illness. An HLA-B27 result cannot supply a personal timetable for symptoms in a sibling. Family discussion should help people recognize concerns worth bringing to a clinician, without making a well child feel that a disease is waiting for them.
Should brothers, sisters or parents be tested?
Testing healthy relatives simply because a child has JSpA is generally not useful. The pediatric part of the ACR 2026 axSpA summary conditionally advises against recommending genetic testing to first-degree relatives. Discussing family risk is a separate matter and can be helpful.
This does not prevent a clinician from investigating a relative who develops relevant symptoms. A sibling with persistent swelling or a change in walking needs their own assessment, rather than a borrowed diagnosis or reassurance based only on HLA-B27. Ask: “Would this test change anything we should do for this person now?” A family screening package is not a substitute for that discussion.
Make the blood draw easier to manage
Tell the service about needle fear, fainting, sensory needs or a previous difficult blood draw. Ask in advance about numbing options, extra time or support from a play specialist. Preparation can include an honest explanation, a comfort item and a choice about looking at the needle. Avoid promising that the procedure will be completely painless.
Follow the instructions for the tests actually ordered. Ask whether food, drink or medicine timing matters; do not fast a child or withhold prescribed medicine on a guess. A teenager may want to choose who stays beside them and how staff explain what is happening.
Leave with a plan for the results
Before leaving, agree who will review the results, how you will hear about them and whom to contact if the expected message does not arrive. A portal alert is not a complete clinical interpretation. If the laboratory or clinical team asks you to seek urgent advice, follow that instruction.
- Which question does each test address?
- What does this result change, and what remains uncertain?
- Which tests need repeating, and who arranges them?
- Which results should we keep for the next clinician?
For the young person, learning one test’s purpose at a time is enough. Understanding the record is a skill that can grow gradually alongside responsibility for care.
Sources and further reading
- MedlinePlus: HLA-B27 antigen
- MedlinePlus: juvenile idiopathic arthritis — examination and tests
- NIAMS: juvenile idiopathic arthritis — diagnosis and monitoring
- ACR/SAA/SPARTAN 2026 axSpA summary — pediatric family counseling, page 14
- ACR: current axSpA guideline publication status
- Royal Free London: preparing a child for a blood test